ARK Genomic Revolution ETF ARKG
49.51 USD +1.22 (+2.53%)
At closeNov 3, 2026, 7:33 PM EST
48.99 -0.52 -1.05%
After hours · Nov 3, 7:33 PM ET
48.79 Day range 50.77
24.60 52-week range 58.83
- YTD
- +70.90%
- 1 year
- +61.48%
- Market cap
- 1.69B
- YTD return
- +70.90%
- 1-year return
- +61.48%
- Volume
- 4.78M
- Avg volume
- 4.71M
- Open
- 48.99
- Previous close
- 48.29
- Day's range
- 48.79 – 50.77
- 52-week range
- 24.60 – 58.83
15m -3.61 (-6.78%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 39.68
- 200-day average
- 32.15
About ARK Genomic Revolution ETF
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
News
ARKG: Revolutionary Science, Unremarkable Returns 
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up 
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You 
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets 
Why Is Tempus AI Stock Falling Friday? 
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs 
What’s Going On With Tempus AI Stock on Monday? 
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For 
Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? 
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Your note
Sign in to keep a note on ARKG — it syncs with the Stock Master app.